Survival Impact of Postoperative Adjuvant Radiotherapy for Treatment of Advanced Stage Maxillary Sinus Cancer Patients
Published: February 1, 2018 | DOI: https://doi.org/10.7860/JCDR/2018/31045.11155
Upendra Nandwana, Manoj Verma, Tej Prakash Soni, Naresh Jakhotia, Nidhi Patni, Anil Kumar Gupta, Lalit Mohan Sharma, Rajesh Pasricha
1. Senior Resident, Department of Radiation Oncology, BMCHRC, Jaipur, Rajasthan, India.
2. Senior Resident, Department of Preventive and Social Medicine, AIIMS, Jodhpur, Rajasthan, India.
3. Consultant, Department of Radiation Oncology, BMCHRC, Jaipur, Rajasthan, India.
4. Consultant, Department of Radiation Oncology, BMCHRC, Jaipur, Rajasthan, India.
5. Consultant, Department of Radiation Oncology, BMCHRC, Jaipur, Rajasthan, India.
6. Consultant, Department of Surgical Oncology, BMCHRC, Jaipur, Rajasthan, India.
7. Consultant, Department of Medical Oncology, BMCHRC, Jaipur, Rajasthan, India.
8. Consultant, Department of Radiation Oncology, AIIMS, Rishikesh, Utharakhand, India.
Correspondence
Dr. Upendra Nandwana,
4 E-17, Rangbari Yojna, Kota-324005, Rajasthan, India.
E-mail: upendranandwana@gmail.com
Introduction: Maxillary sinus cancer is a rare disease and usually present in advanced stage. Limited clinical data exists from India about the use of adjuvant radiotherapy in advanced cases and survival thereafter.
Aim: To study survival and identify prognostic factors of importance in patients irradiated postoperatively for advanced stage maxillary sinus carcinoma.
Materials and Methods: Medical records of 25 patients of advanced stage maxillary sinus carcinoma treated with curative intent from January 2011 to November 2016 were analysed retrospectively. All the patients underwent primary surgery followed by postoperative adjuvant radiotherapy. Survival analysis was done using Kaplan-Meier method.
Results: All patients presented with advanced disease Stage III or IV; nodal involvement was observed in 5 (20%) patients. The three-year overall survival after surgery and postoperative radiotherapy with or without concurrent chemotherapy was 74%. Median survival was 17 months. Most common pattern of recurrence was at the primary site, observed in 5 (20%) patients. Lymph node involvement, pT4 lesion, surgical margins positive, depth of invasion >10 mm, high grade, lymphovascular/perineural invasion were prognostic factors of importance.
Conclusion: Primary surgical treatment of maxillary sinus carcinoma in advanced stage followed by postoperative adjuvant radiotherapy is a good treatment option.
[
FULL TEXT ] | [ PDF]